Literature DB >> 24503066

Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.

John S Albin1, William L Brown1, Reuben S Harris2.   

Abstract

APOBEC3 proteins are DNA cytosine deaminases that restrict the replication of human immunodeficiency virus deficient in the counterdefense protein Vif. Here, we address the capacity of APOBEC3F to restrict via deaminase-dependent and -independent mechanisms by monitoring spreading infections in diverse T cell lines. Our data indicate that only a deaminase-proficient protein is capable of long-term restriction of Vif-deficient HIV in T cells, analogous to prior reports for APOBEC3G. This indicates that the principal mechanism of APOBEC3F restriction is deaminase-dependent.
© 2013 Published by Elsevier Inc.

Entities:  

Keywords:  APOBEC3F; APOBEC3G; Deaminase; HIV restriction; Vif

Mesh:

Substances:

Year:  2013        PMID: 24503066      PMCID: PMC3932626          DOI: 10.1016/j.virol.2013.11.041

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  47 in total

1.  Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.

Authors:  Fei Guo; Shan Cen; Meijuan Niu; Jenan Saadatmand; Lawrence Kleiman
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

2.  Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity.

Authors:  Tomoki Yamashita; Masako Nomaguchi; Ariko Miyake; Tsuneo Uchiyama; Akio Adachi
Journal:  Microbes Infect       Date:  2009-11-26       Impact factor: 2.700

3.  Different interaction between HIV-1 Vif and its cellular target proteins APOBEC3G/APOBEC3F.

Authors:  Tamiko Nagao; Tomoki Yamashita; Ariko Miyake; Tsuneo Uchiyama; Masako Nomaguchi; Akio Adachi
Journal:  J Med Invest       Date:  2010-02

4.  Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G.

Authors:  Bärbel Schröfelbauer; Tilo Senger; Gerard Manning; Nathaniel R Landau
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes.

Authors:  Lubbertus C F Mulder; Marcel Ooms; Susan Majdak; Jordan Smedresman; Caitlin Linscheid; Ariana Harari; Andrea Kunz; Viviana Simon
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

6.  APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms.

Authors:  Jean L Mbisa; Wei Bu; Vinay K Pathak
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

7.  Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction.

Authors:  Eric W Refsland; Mark D Stenglein; Keisuke Shindo; John S Albin; William L Brown; Reuben S Harris
Journal:  Nucleic Acids Res       Date:  2010-03-22       Impact factor: 16.971

8.  Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.

Authors:  Eri Miyagi; Sandrine Opi; Hiroaki Takeuchi; Mohammad Khan; Ritu Goila-Gaur; Sandra Kao; Klaus Strebel
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

9.  Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.

Authors:  Kun Luo; Tao Wang; Bindong Liu; Chunjuan Tian; Zuoxiang Xiao; John Kappes; Xiao-Fang Yu
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

10.  APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.

Authors:  Yanxing Han; Xiaojun Wang; Ying Dang; Yong-Hui Zheng
Journal:  PLoS Pathog       Date:  2008-07-04       Impact factor: 6.823

View more
  14 in total

1.  APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.

Authors:  John F Krisko; Nurjahan Begum; Caroline E Baker; John L Foster; J Victor Garcia
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

Review 2.  APOBECs and virus restriction.

Authors:  Reuben S Harris; Jaquelin P Dudley
Journal:  Virology       Date:  2015-03-26       Impact factor: 3.616

3.  The in vitro Biochemical Characterization of an HIV-1 Restriction Factor APOBEC3F: Importance of Loop 7 on Both CD1 and CD2 for DNA Binding and Deamination.

Authors:  Qihan Chen; Xiao Xiao; Aaron Wolfe; Xiaojiang S Chen
Journal:  J Mol Biol       Date:  2016-04-08       Impact factor: 5.469

4.  Long-term passage of Vif-null HIV-1 in CD4+ T cells expressing sub-lethal levels of APOBEC proteins fails to develop APOBEC resistance.

Authors:  Eri Miyagi; Sandra Kao; Miyoshi Fumitaka; Alicia Buckler-White; Ron Plishka; Klaus Strebel
Journal:  Virology       Date:  2017-01-25       Impact factor: 3.616

Review 5.  Multiple Inhibitory Factors Act in the Late Phase of HIV-1 Replication: a Systematic Review of the Literature.

Authors:  Jean-François Gélinas; Deborah R Gill; Stephen C Hyde
Journal:  Microbiol Mol Biol Rev       Date:  2018-01-10       Impact factor: 11.056

Review 6.  Intrinsic host restrictions to HIV-1 and mechanisms of viral escape.

Authors:  Viviana Simon; Nicolin Bloch; Nathaniel R Landau
Journal:  Nat Immunol       Date:  2015-06       Impact factor: 25.606

7.  Differential Activity of APOBEC3F, APOBEC3G, and APOBEC3H in the Restriction of HIV-2.

Authors:  Morgan E Meissner; Nora A Willkomm; Jamie Lucas; William G Arndt; Sarah F Aitken; Emily J Julik; Sunanda Baliga; Louis M Mansky
Journal:  J Mol Biol       Date:  2021-11-10       Impact factor: 5.469

8.  1.92 Angstrom Zinc-Free APOBEC3F Catalytic Domain Crystal Structure.

Authors:  Nadine M Shaban; Ke Shi; Ming Li; Hideki Aihara; Reuben S Harris
Journal:  J Mol Biol       Date:  2016-04-30       Impact factor: 5.469

Review 9.  Suppression of APOBEC3-mediated restriction of HIV-1 by Vif.

Authors:  Yuqing Feng; Tayyba T Baig; Robin P Love; Linda Chelico
Journal:  Front Microbiol       Date:  2014-08-26       Impact factor: 5.640

10.  APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model.

Authors:  Kei Sato; Junko S Takeuchi; Naoko Misawa; Taisuke Izumi; Tomoko Kobayashi; Yuichi Kimura; Shingo Iwami; Akifumi Takaori-Kondo; Wei-Shau Hu; Kazuyuki Aihara; Mamoru Ito; Dong Sung An; Vinay K Pathak; Yoshio Koyanagi
Journal:  PLoS Pathog       Date:  2014-10-16       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.